+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Benign Prostatic Hyperplasia Treatment Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type- Product Image
Benign Prostatic Hyperplasia Treatment Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type- Product Image
New

Benign Prostatic Hyperplasia Treatment Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type

  • PDF Icon

    Report

  • 96 Pages
  • January 2025
  • Region: Global
  • Prof Research
  • ID: 5968910
Description Jump to:
Benign Prostatic Hyperplasia (BPH), a non-cancerous enlargement of the prostate gland, is a common condition that affects nearly half of men aged 50 and older, with prevalence rising to about 90% in those aged 80 and above. As the aging population grows, the demand for effective treatment options for BPH continues to expand. The BPH treatment drug market is characterized by a wide array of medications aimed at alleviating symptoms, improving urinary flow, and reducing the size of the prostate gland. This report explores the market landscape, providing insight into market size, share, trends, and forecasts for the period 2024 - 2029.

Market Size and Growth

As of 2023, the global market for BPH treatment drugs is estimated to be valued at approximately USD 5.5 billion. This market is projected to grow at a compound annual growth rate (CAGR) of 6.5% from 2024 to 2029, reaching an estimated USD 7.6 billion by the end of the forecast period. This growth is primarily driven by increasing prevalence of BPH, advancing healthcare infrastructure, and a growing focus on men's health and wellness.

Market Share & Trends Analysis

The BPH treatment drug market can be segmented by product type, key players, process applications, end-use, and region.

By Product Type

The market is broadly categorized into various drug classes:
  • Alpha Blockers: These are among the most commonly prescribed medications for BPH. Major drugs include Alfuzosin, Doxazosin, Tamsulosin, Terazosin, and Silodosin. Collectively, alpha blockers hold a significant share, approximately 40% of the total BPH drug market, due to their quick action in relieving urinary symptoms.
  • 5-alpha Reductase Inhibitors: Dutasteride and Finasteride are prominent players in this category, accounting for around 25% market share. These medications work by inhibiting the hormonal changes that lead to prostate enlargement.
  • PDE5 Inhibitors: Tadalafil, primarily known for its use in erectile dysfunction, has shown efficacy in BPH treatment as well. This segment represents about 15% of the market.
  • Anticholinergics: Oxybutynin and Tolterodine are used primarily to manage overactive bladder symptoms associated with BPH, making up around 10% of the market.
  • Beta-3 Agonists: Solifenacin and Mirabegron are emerging options, together capturing about 10% of the market share.

Key Players

The competitive landscape of the BPH treatment drug market features several key players that significantly influence trends and innovations. Notable companies include:
  • Sanofi
  • Pfizer
  • AbbVie
  • Viatris
  • Waylis Therapeutics
  • Organon
  • Eli Lilly
  • Johnson & Johnson
  • Astellas Pharma
These companies invest heavily in research and development to enhance existing treatment options and introduce new therapeutic agents to the market. With a robust pipeline of innovative drugs, these players are set to maintain a stronghold in the BPH therapeutics domain.

By Application

Applications of BPH treatment drugs primarily cater to symptomatic relief and management of prostate enlargement conditions. Key applications include:
  • Symptomatic Relief: Focused on alleviating urinary tract symptoms including urgency, frequency, and flow obstruction.
  • Prostate Volume Reduction: Targeted therapies aim to reduce the size of the prostate in order to improve urinary function and quality of life for patients.

By End-Use

The end-use segment for BPH treatment drugs includes:
  • Hospitals: A major setting where BPH treatment is initiated and monitored, especially for severe cases that may require surgical intervention.
  • Outpatient Clinics: Patients often visit clinics for ongoing management and follow-up care of BPH treatment.
  • Pharmacies: Retail pharmacies provide easy access to prescription and over-the-counter medications for BPH.

Regional Insights

The BPH treatment drug market is represented across various regions, each with unique dynamics contributing to market growth:
  • North America: This region holds the largest share of the market due to a high prevalence of BPH, advanced healthcare systems, and the presence of key pharmaceutical companies. Market growth is projected at about 7% from 2024 to 2029.
  • Europe: The European market is equally significant, growing at a CAGR of approximately 6%. An aging population and increased awareness of men's health issues fuel market expansion.
  • Asia-Pacific: Rapid population growth and improving healthcare access contribute to a robust CAGR of 8% in this region, making it one of the fastest-growing markets for BPH treatments.
  • Latin America & Middle East & Africa: These regions are witnessing steady growth but face challenges such as healthcare infrastructure and access to medicines.

Market News and Policies

Recent advances and regulatory changes are actively reshaping the BPH treatment landscape:
  • FDA Approvals: Continuous approvals of new drugs and formulations are being reported, expanding treatment options for patients.
  • Research Initiatives: Increased funding for research into novel therapeutics, including combination therapies that can address multiple aspects of BPH simultaneously.
  • Healthcare Policies: Improvements in health insurance coverage for men's health medications are making treatments more accessible and affordable.

Segment Forecasts (2024 - 2029)

The BPH treatment drug market is projected to evolve significantly over the next several years:
  • The alpha blockers segment will remain dominant, but competition from 5-alpha reductase inhibitors will escalate as more studies validate their long-term benefits.
  • PDE5 inhibitors like Tadalafil will witness increased adoption in clinical practice for dual management of ED and BPH, thereby expanding this segment.
  • Innovative treatments focusing on non-pharmacological solutions such as prostate artery embolization may emerge, changing the treatment paradigm.

Conclusion

The Benign Prostatic Hyperplasia Treatment Drug Market is poised for substantial growth driven by increasing prevalence, enhanced treatment options, and progressive healthcare policies. A thorough understanding of the market dynamics, including product type segmentation and end-use factors, will enable stakeholders to navigate this evolving landscape effectively. As both the aging population and awareness of men's health issues continue to rise, the market for BPH treatments will remain robust, presenting numerous opportunities for pharmaceutical companies, healthcare professionals, and patients alike.

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1 Executive SummaryChapter 2 Abbreviation and Acronyms
Chapter 3 Preface
3.1 Research Scope
3.2 Research Sources
3.2.1 Data Sources
3.2.2 Assumptions
3.3 Research Method
Chapter 4 Market Landscape
4.1 Market Overview
4.2 Classification/Types
4.3 Application/End Users
Chapter 5 Market Trend Analysis
5.1 Introduction
5.2 Drivers
5.3 Restraints
5.4 Opportunities
5.5 Threats
Chapter 6 Industry Chain Analysis
6.1 Upstream/Suppliers Analysis
6.2 Benign Prostatic Hyperplasia Treatment Drug Analysis
6.2.1 Technology Analysis
6.2.2 Cost Analysis
6.2.3 Market Channel Analysis
6.3 Downstream Buyers/End Users
Chapter 7 Latest Market Dynamics
7.1 Latest News
7.2 Merger and Acquisition
7.3 Planned/Future Project
7.4 Policy Dynamics
Chapter 8 Historical and Forecast Benign Prostatic Hyperplasia Treatment Drug Market in North America (2020-2030)
8.1 Benign Prostatic Hyperplasia Treatment Drug Market Size
8.2 Benign Prostatic Hyperplasia Treatment Drug Market by End Use
8.3 Competition by Players/Suppliers
8.4 Benign Prostatic Hyperplasia Treatment Drug Market Size by Type
8.5 Key Countries Analysis
8.5.1 United States
8.5.2 Canada
8.5.3 Mexico
Chapter 9 Historical and Forecast Benign Prostatic Hyperplasia Treatment Drug Market in South America (2020-2030)
9.1 Benign Prostatic Hyperplasia Treatment Drug Market Size
9.2 Benign Prostatic Hyperplasia Treatment Drug Market by End Use
9.3 Competition by Players/Suppliers
9.4 Benign Prostatic Hyperplasia Treatment Drug Market Size by Type
9.5 Key Countries Analysis
9.5.1 Brazil
9.5.2 Argentina
9.5.3 Chile
9.5.4 Peru
Chapter 10 Historical and Forecast Benign Prostatic Hyperplasia Treatment Drug Market in Asia & Pacific (2020-2030)
10.1 Benign Prostatic Hyperplasia Treatment Drug Market Size
10.2 Benign Prostatic Hyperplasia Treatment Drug Market by End Use
10.3 Competition by Players/Suppliers
10.4 Benign Prostatic Hyperplasia Treatment Drug Market Size by Type
10.5 Key Countries Analysis
10.5.1 China
10.5.2 India
10.5.3 Japan
10.5.4 South Korea
10.5.5 Southeast Asia
10.5.6 Australia
Chapter 11 Historical and Forecast Benign Prostatic Hyperplasia Treatment Drug Market in Europe (2020-2030)
11.1 Benign Prostatic Hyperplasia Treatment Drug Market Size
11.2 Benign Prostatic Hyperplasia Treatment Drug Market by End Use
11.3 Competition by Players/Suppliers
11.4 Benign Prostatic Hyperplasia Treatment Drug Market Size by Type
11.5 Key Countries Analysis
11.5.1 Germany
11.5.2 France
11.5.3 United Kingdom
11.5.4 Italy
11.5.5 Spain
11.5.6 Belgium
11.5.7 Netherlands
11.5.8 Austria
11.5.9 Poland
11.5.10 Russia
Chapter 12 Historical and Forecast Benign Prostatic Hyperplasia Treatment Drug Market in MEA (2020-2030)
12.1 Benign Prostatic Hyperplasia Treatment Drug Market Size
12.2 Benign Prostatic Hyperplasia Treatment Drug Market by End Use
12.3 Competition by Players/Suppliers
12.4 Benign Prostatic Hyperplasia Treatment Drug Market Size by Type
12.5 Key Countries Analysis
12.5.1 Egypt
12.5.2 Israel
12.5.3 South Africa
12.5.4 Gulf Cooperation Council Countries
12.5.5 Turkey
Chapter 13 Summary For Global Benign Prostatic Hyperplasia Treatment Drug Market (2020-2025)
13.1 Benign Prostatic Hyperplasia Treatment Drug Market Size
13.2 Benign Prostatic Hyperplasia Treatment Drug Market by End Use
13.3 Competition by Players/Suppliers
13.4 Benign Prostatic Hyperplasia Treatment Drug Market Size by Type
Chapter 14 Global Benign Prostatic Hyperplasia Treatment Drug Market Forecast (2025-2030)
14.1 Benign Prostatic Hyperplasia Treatment Drug Market Size Forecast
14.2 Benign Prostatic Hyperplasia Treatment Drug Application Forecast
14.3 Competition by Players/Suppliers
14.4 Benign Prostatic Hyperplasia Treatment Drug Type Forecast
Chapter 15 Analysis of Global Key Vendors
15.1 Sanofi
15.1.1 Company Profile
15.1.2 Main Business and Benign Prostatic Hyperplasia Treatment Drug Information
15.1.3 SWOT Analysis of Sanofi
15.1.4 Sanofi Benign Prostatic Hyperplasia Treatment Drug Revenue, Gross Margin and Market Share (2020-2025)
15.2 Pfizer
15.2.1 Company Profile
15.2.2 Main Business and Benign Prostatic Hyperplasia Treatment Drug Information
15.2.3 SWOT Analysis of Pfizer
15.2.4 Pfizer Benign Prostatic Hyperplasia Treatment Drug Revenue, Gross Margin and Market Share (2020-2025)
15.3 AbbVie
15.3.1 Company Profile
15.3.2 Main Business and Benign Prostatic Hyperplasia Treatment Drug Information
15.3.3 SWOT Analysis of AbbVie
15.3.4 AbbVie Benign Prostatic Hyperplasia Treatment Drug Revenue, Gross Margin and Market Share (2020-2025)
15.4 Viatris
15.4.1 Company Profile
15.4.2 Main Business and Benign Prostatic Hyperplasia Treatment Drug Information
15.4.3 SWOT Analysis of Viatris
15.4.4 Viatris Benign Prostatic Hyperplasia Treatment Drug Revenue, Gross Margin and Market Share (2020-2025)
15.5 Waylis Therapeutics
15.5.1 Company Profile
15.5.2 Main Business and Benign Prostatic Hyperplasia Treatment Drug Information
15.5.3 SWOT Analysis of Waylis Therapeutics
15.5.4 Waylis Therapeutics Benign Prostatic Hyperplasia Treatment Drug Revenue, Gross Margin and Market Share (2020-2025)
15.6 Organon
15.6.1 Company Profile
15.6.2 Main Business and Benign Prostatic Hyperplasia Treatment Drug Information
15.6.3 SWOT Analysis of Organon
15.6.4 Organon Benign Prostatic Hyperplasia Treatment Drug Revenue, Gross Margin and Market Share (2020-2025)
15.7 Eli Lilly
15.7.1 Company Profile
15.7.2 Main Business and Benign Prostatic Hyperplasia Treatment Drug Information
15.7.3 SWOT Analysis of Eli Lilly
15.7.4 Eli Lilly Benign Prostatic Hyperplasia Treatment Drug Revenue, Gross Margin and Market Share (2020-2025)
15.8 Johnson & Johnson
15.8.1 Company Profile
15.8.2 Main Business and Benign Prostatic Hyperplasia Treatment Drug Information
15.8.3 SWOT Analysis of Johnson & Johnson
15.8.4 Johnson & Johnson Benign Prostatic Hyperplasia Treatment Drug Revenue, Gross Margin and Market Share (2020-2025)
15.9 Astellas Pharma
15.9.1 Company Profile
15.9.2 Main Business and Benign Prostatic Hyperplasia Treatment Drug Information
15.9.3 SWOT Analysis of Astellas Pharma
15.9.4 Astellas Pharma Benign Prostatic Hyperplasia Treatment Drug Revenue, Gross Margin and Market Share (2020-2025)
List of Tables and Figures
Table Abbreviation and Acronyms
Table Research Scope of Benign Prostatic Hyperplasia Treatment Drug Report
Table Data Sources of Benign Prostatic Hyperplasia Treatment Drug Report
Table Major Assumptions of Benign Prostatic Hyperplasia Treatment Drug Report
Figure Market Size Estimated Method
Figure Major Forecasting Factors
Figure Benign Prostatic Hyperplasia Treatment Drug Picture
Table Benign Prostatic Hyperplasia Treatment Drug Classification
Table Benign Prostatic Hyperplasia Treatment Drug Applications
Table Drivers of Benign Prostatic Hyperplasia Treatment Drug Market
Table Restraints of Benign Prostatic Hyperplasia Treatment Drug Market
Table Opportunities of Benign Prostatic Hyperplasia Treatment Drug Market
Table Threats of Benign Prostatic Hyperplasia Treatment Drug Market
Table COVID-19 Impact For Benign Prostatic Hyperplasia Treatment Drug Market
Table Raw Materials Suppliers
Table Different Production Methods of Benign Prostatic Hyperplasia Treatment Drug
Table Cost Structure Analysis of Benign Prostatic Hyperplasia Treatment Drug
Table Key End Users
Table Latest News of Benign Prostatic Hyperplasia Treatment Drug Market
Table Merger and Acquisition
Table Planned/Future Project of Benign Prostatic Hyperplasia Treatment Drug Market
Table Policy of Benign Prostatic Hyperplasia Treatment Drug Market
Table 2020-2030 North America Benign Prostatic Hyperplasia Treatment Drug Market Size
Figure 2020-2030 North America Benign Prostatic Hyperplasia Treatment Drug Market Size and CAGR
Table 2020-2030 North America Benign Prostatic Hyperplasia Treatment Drug Market Size by Application
Table 2020-2025 North America Benign Prostatic Hyperplasia Treatment Drug Key Players Revenue
Table 2020-2025 North America Benign Prostatic Hyperplasia Treatment Drug Key Players Market Share
Table 2020-2030 North America Benign Prostatic Hyperplasia Treatment Drug Market Size by Type
Table 2020-2030 United States Benign Prostatic Hyperplasia Treatment Drug Market Size
Table 2020-2030 Canada Benign Prostatic Hyperplasia Treatment Drug Market Size
Table 2020-2030 Mexico Benign Prostatic Hyperplasia Treatment Drug Market Size
Table 2020-2030 South America Benign Prostatic Hyperplasia Treatment Drug Market Size
Figure 2020-2030 South America Benign Prostatic Hyperplasia Treatment Drug Market Size and CAGR
Table 2020-2030 South America Benign Prostatic Hyperplasia Treatment Drug Market Size by Application
Table 2020-2025 South America Benign Prostatic Hyperplasia Treatment Drug Key Players Revenue
Table 2020-2025 South America Benign Prostatic Hyperplasia Treatment Drug Key Players Market Share
Table 2020-2030 South America Benign Prostatic Hyperplasia Treatment Drug Market Size by Type
Table 2020-2030 Brazil Benign Prostatic Hyperplasia Treatment Drug Market Size
Table 2020-2030 Argentina Benign Prostatic Hyperplasia Treatment Drug Market Size
Table 2020-2030 Chile Benign Prostatic Hyperplasia Treatment Drug Market Size
Table 2020-2030 Peru Benign Prostatic Hyperplasia Treatment Drug Market Size
Table 2020-2030 Asia & Pacific Benign Prostatic Hyperplasia Treatment Drug Market Size
Figure 2020-2030 Asia & Pacific Benign Prostatic Hyperplasia Treatment Drug Market Size and CAGR
Table 2020-2030 Asia & Pacific Benign Prostatic Hyperplasia Treatment Drug Market Size by Application
Table 2020-2025 Asia & Pacific Benign Prostatic Hyperplasia Treatment Drug Key Players Revenue
Table 2020-2025 Asia & Pacific Benign Prostatic Hyperplasia Treatment Drug Key Players Market Share
Table 2020-2030 Asia & Pacific Benign Prostatic Hyperplasia Treatment Drug Market Size by Type
Table 2020-2030 China Benign Prostatic Hyperplasia Treatment Drug Market Size
Table 2020-2030 India Benign Prostatic Hyperplasia Treatment Drug Market Size
Table 2020-2030 Japan Benign Prostatic Hyperplasia Treatment Drug Market Size
Table 2020-2030 South Korea Benign Prostatic Hyperplasia Treatment Drug Market Size
Table 2020-2030 Southeast Asia Benign Prostatic Hyperplasia Treatment Drug Market Size
Table 2020-2030 Australia Benign Prostatic Hyperplasia Treatment Drug Market Size
Table 2020-2030 Europe Benign Prostatic Hyperplasia Treatment Drug Market Size
Figure 2020-2030 Europe Benign Prostatic Hyperplasia Treatment Drug Market Size and CAGR
Table 2020-2030 Europe Benign Prostatic Hyperplasia Treatment Drug Market Size by Application
Table 2020-2025 Europe Benign Prostatic Hyperplasia Treatment Drug Key Players Revenue
Table 2020-2025 Europe Benign Prostatic Hyperplasia Treatment Drug Key Players Market Share
Table 2020-2030 Europe Benign Prostatic Hyperplasia Treatment Drug Market Size by Type
Table 2020-2030 Germany Benign Prostatic Hyperplasia Treatment Drug Market Size
Table 2020-2030 France Benign Prostatic Hyperplasia Treatment Drug Market Size
Table 2020-2030 United Kingdom Benign Prostatic Hyperplasia Treatment Drug Market Size
Table 2020-2030 Italy Benign Prostatic Hyperplasia Treatment Drug Market Size
Table 2020-2030 Spain Benign Prostatic Hyperplasia Treatment Drug Market Size
Table 2020-2030 Belgium Benign Prostatic Hyperplasia Treatment Drug Market Size
Table 2020-2030 Netherlands Benign Prostatic Hyperplasia Treatment Drug Market Size
Table 2020-2030 Austria Benign Prostatic Hyperplasia Treatment Drug Market Size
Table 2020-2030 Poland Benign Prostatic Hyperplasia Treatment Drug Market Size
Table 2020-2030 Russia Benign Prostatic Hyperplasia Treatment Drug Market Size
Table 2020-2030 MEA Benign Prostatic Hyperplasia Treatment Drug Market Size
Figure 2020-2030 MEA Benign Prostatic Hyperplasia Treatment Drug Market Size and CAGR
Table 2020-2030 MEA Benign Prostatic Hyperplasia Treatment Drug Market Size by Application
Table 2020-2025 MEA Benign Prostatic Hyperplasia Treatment Drug Key Players Revenue
Table 2020-2025 MEA Benign Prostatic Hyperplasia Treatment Drug Key Players Market Share
Table 2020-2030 MEA Benign Prostatic Hyperplasia Treatment Drug Market Size by Type
Table 2020-2030 Egypt Benign Prostatic Hyperplasia Treatment Drug Market Size
Table 2020-2030 Israel Benign Prostatic Hyperplasia Treatment Drug Market Size
Table 2020-2030 South Africa Benign Prostatic Hyperplasia Treatment Drug Market Size
Table 2020-2030 Gulf Cooperation Council Countries Benign Prostatic Hyperplasia Treatment Drug Market Size
Table 2020-2030 Turkey Benign Prostatic Hyperplasia Treatment Drug Market Size
Table 2020-2025 Global Benign Prostatic Hyperplasia Treatment Drug Market Size by Region
Table 2020-2025 Global Benign Prostatic Hyperplasia Treatment Drug Market Size Share by Region
Table 2020-2025 Global Benign Prostatic Hyperplasia Treatment Drug Market Size by Application
Table 2020-2025 Global Benign Prostatic Hyperplasia Treatment Drug Market Share by Application
Table 2020-2025 Global Benign Prostatic Hyperplasia Treatment Drug Key Vendors Revenue
Figure 2020-2025 Global Benign Prostatic Hyperplasia Treatment Drug Market Size and Growth Rate
Table 2020-2025 Global Benign Prostatic Hyperplasia Treatment Drug Key Vendors Market Share
Table 2020-2025 Global Benign Prostatic Hyperplasia Treatment Drug Market Size by Type
Table 2020-2025 Global Benign Prostatic Hyperplasia Treatment Drug Market Share by Type
Table 2025-2030 Global Benign Prostatic Hyperplasia Treatment Drug Market Size by Region
Table 2025-2030 Global Benign Prostatic Hyperplasia Treatment Drug Market Size Share by Region
Table 2025-2030 Global Benign Prostatic Hyperplasia Treatment Drug Market Size by Application
Table 2025-2030 Global Benign Prostatic Hyperplasia Treatment Drug Market Share by Application
Table 2025-2030 Global Benign Prostatic Hyperplasia Treatment Drug Key Vendors Revenue
Figure 2025-2030 Global Benign Prostatic Hyperplasia Treatment Drug Market Size and Growth Rate
Table 2025-2030 Global Benign Prostatic Hyperplasia Treatment Drug Key Vendors Market Share
Table 2025-2030 Global Benign Prostatic Hyperplasia Treatment Drug Market Size by Type
Table 2025-2030 Benign Prostatic Hyperplasia Treatment Drug Global Market Share by Type

Companies Mentioned

  • Sanofi
  • Pfizer
  • AbbVie
  • Viatris
  • Waylis Therapeutics
  • Organon
  • Eli Lilly
  • Johnson & Johnson
  • Astellas Pharma

Related Topics

Related Reports

Benign prostatic hyperplasia (BPH) - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Benign prostatic hyperplasia (BPH) - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Benign Prostatic Hyperplasia Treatment Market by Therapeutic Class, Therapy, End User - Global Forecast 2025-2030 - Product Image

Benign Prostatic Hyperplasia Treatment Market by Therapeutic Class, Therapy, End User - Global Forecast 2025-2030

  • Report
  • 181 Pages
  • Global
From
Benign Prostatic Hyperplasia (BPH) Drugs - Global Strategic Business Report - Product Image

Benign Prostatic Hyperplasia (BPH) Drugs - Global Strategic Business Report

  • Report
  • 182 Pages
  • Global
From
Benign prostatic hyperplasia - Pipeline Insight, 2024 - Product Image

Benign prostatic hyperplasia - Pipeline Insight, 2024

  • Clinical Trials
  • 60 Pages
  • Global
From
Benign Prostatic Hyperplasia Treatment Market Report by Treatment Type, and Region 2024-2032 - Product Image

Benign Prostatic Hyperplasia Treatment Market Report by Treatment Type, and Region 2024-2032

  • Report
  • 148 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.